Get started

Financials · RYTM

Rhythm Pharmaceuticals Inc. (RYTM) financials

For the twelve months ended Sep 30, 2026, Rhythm Pharmaceuticals Inc. reported $280.75M of revenue and -$193.81M of net income.

Revenue, TTM
$280.75M
Revenue growth, YoY
+61.0%
Net income, TTM
-$193.81M
Net margin
-69.0%
EPS, diluted, TTM
-$2.90
Cash
$39.98M
Total debt
$102.67M
P/S
28.14
Market cap
$7.90B
Annual revenue$189.76M
FY2016FY2025
Annual net income-$196.54M
FY2016FY2025
Annual free cash flow-$116.63M
FY2016FY2025

RYTM revenue and earnings growth

RYTM revenueQ3 2026$92.13M

Quarter YoY
+79.6%
QoQ
+29.3%
FY YoY
+45.8%

RYTM revenue was $92.13M in fiscal Q3 2026 (ended Sep 30, 2026), up 79.6% from a year earlier and up 29.3% from the prior quarter. For the full fiscal 2025 it was $189.76M, up 45.8% from fiscal 2024. It rose in each of the last 4 fiscal years. Fiscal 2025 is the highest of the 10 fiscal years on file.

RYTM net incomeQ3 2026-$41.37M

RYTM net income was -$41.37M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$52.90M a year earlier. For the full fiscal 2025 it was -$196.54M, compared with -$260.60M in fiscal 2024.

RYTM EPSQ3 2026-$0.61

RYTM diluted EPS was -$0.61 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.82 a year earlier. For the full fiscal 2025 it was -$3.11, compared with -$4.34 in fiscal 2024.

RYTM free cash flowQ4 2025-$26.34M

RYTM free cash flow was -$26.34M in fiscal Q4 2025 (ended Dec 31, 2025). For the full fiscal 2025 it was -$116.63M, compared with -$113.88M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$189.76M$130.13M$77.43M$23.64M$3.15M$0$0$0$0$0
Cost of revenue$19.49M$13.37M$9.30M$2.13M$599.0K-----
Gross profit$170.26M$116.76M$68.13M$21.50M$2.56M-----
Research and development$167.34M$237.96M$134.95M$108.63M$104.13M$90.45M$109.45M$50.34M$22.89M$19.59M
Selling, general and admin$194.94M$144.30M$117.53M$92.03M$68.49M$46.13M$36.55M$28.08M$9.52M$6.31M
Operating income-$192.02M-$265.50M-$184.36M-$179.16M-$170.06M-$136.57M-$146.00M-$78.42M-$32.41M-$25.91M
Interest expense$20.58M$20.60M$13.89M$5.20M------
Pre-tax income-$196.04M-$260.26M-$184.11M-$181.12M-$69.61M-----
Income tax$497.0K$346.0K$564.0K-------
Net income-$196.54M-$260.60M-$184.68M-$181.12M-$69.61M-$134.00M-$140.73M-$74.06M-$33.71M-$29.07M
EPS, basic-$3.11-$4.34-$3.20-$3.47-$1.40-$3.04-$3.86-$2.39-$2.83-$2.85
EPS, diluted-$3.11-$4.34-$3.20-$3.47-$1.40-$3.04-$3.86-$2.39-$2.83-$2.85
Diluted shares65.0M61.0M57.7M52.1M49.6M44.1M36.4M31.0M13.3M10.2M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$54.30M$89.14M$60.08M$127.68M$59.25M$100.85M$62.70M$49.94M$34.46M$6.76M
Short-term investments$334.65M$231.43M$215.76M$205.61M$235.61M$71.94M$230.16M---
Receivables$26.08M$18.51M$14.87M$6.22M$1.02M-----
Inventory$25.75M$18.74M$8.62M$2.92M$111.0K-----
Current assets$466.92M$374.20M$308.27M$354.24M$308.39M$181.67M$302.40M$258.69M$150.67M$11.18M
Total assets$480.20M$392.27M$332.75M$382.48M$329.52M$187.07M$308.52M$260.21M$151.74M$12.34M
Current liabilities$105.94M$115.52M$55.20M$39.81M$43.43M$17.99M$24.42M$13.58M$6.72M$4.73M
Short-term debt$7.30M$1.54M--------
Long-term debt$100.89M$108.27M$106.14M-------
Total debt$108.18M$109.81M$106.14M-------
Total liabilities$210.17M$227.72M$162.99M$118.22M$45.37M$20.55M$27.50M$13.95M$6.95M$5.04M
Shareholders' equity$139.07M$21.73M$169.76M$264.26M$284.15M$166.53M$281.02M$246.26M$144.79M-$32.70M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$115.67M-$113.88M-$136.16M-$173.43M-$146.00M-$121.98M-$122.75M-$62.06M-$29.46M-$23.22M
Capital expenditures$953.0K$0$47.0K$281.0K$434.0K$214.0K$3.38M$722.0K$133.0K$1.06M
Free cash flow-$116.63M-$113.88M-$136.20M-$173.71M-$146.44M-$122.19M-$126.14M-$62.78M-$29.59M-$24.28M
Investing cash flow-$137.15M-$48.17M-$5.67M$28.03M-$62.16M$158.53M-$27.97M-$87.15M-$110.04M-$5.11M
Financing cash flow$217.96M$191.24M$74.37M$213.83M$166.48M$2.01M$163.47M$164.69M$167.20M-
Stock-based compensation$66.82M$39.68M$32.55M$19.83M$20.80M$17.45M$11.88M$6.39M$2.28M$1.17M
Depreciation and amortization$500.0K$700.0K$900.0K$896.0K$816.0K$690.0K$834.0K$442.0K$223.0K$144.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY45.8%68.1%227.6%649.5%------
Gross margin89.7%89.7%88.0%91.0%81.0%-----
Operating margin-101.2%-204.0%-238.1%-757.9%-5391.9%-----
Net margin-103.6%-200.3%-238.5%-766.2%-2207.1%-----
Free cash flow margin-61.5%-87.5%-175.9%-734.9%-4642.9%-----
Return on equity-141.3%-1199.3%-108.8%-68.5%-24.5%-80.5%-50.1%-30.1%-23.3%-
Return on assets-40.9%-66.4%-55.5%-47.4%-21.1%-71.6%-45.6%-28.5%-22.2%-235.6%
Current ratio4.413.245.588.907.1010.1012.3819.0522.422.36
Debt to equity0.785.050.63-------

Source: XBRL data Rhythm Pharmaceuticals Inc. files with the SEC, latest filing dated Nov 3, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

RYTM peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
RYTM$280.75M+61.0%-$193.81M-69.0%$7.90B
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

RYTM FAQ

8 questions
  • What is RYTM revenue?
    Rhythm Pharmaceuticals Inc. (RYTM) reported $280.75M of revenue for the twelve months ended Sep 30, 2026. That is up 61.0% from the year before. Revenue for fiscal 2025 was $189.76M.
  • Is RYTM profitable?
    No. Rhythm Pharmaceuticals Inc. reported a net loss of $193.81M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does RYTM have?
    Rhythm Pharmaceuticals Inc. reported $39.98M in cash and cash equivalents and $102.67M of debt on its most recent balance sheet in SEC filings.
  • How fast is RYTM revenue growing?
    Rhythm Pharmaceuticals Inc.'s revenue changed +45.8% in fiscal 2025, to $189.76M.
  • What is RYTM gross margin?
    Rhythm Pharmaceuticals Inc.'s gross profit was $247.69M on $280.75M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 88.2%.
  • What is RYTM earnings per share?
    Diluted earnings per share were -$2.90 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did RYTM last report financial results?
    The latest statements here come from Rhythm Pharmaceuticals Inc.'s 10-Q filed on Nov 3, 2026, covering the period ended Sep 30, 2026.
  • Where does this RYTM financial data come from?
    Quantisnow builds these statements from the structured XBRL data Rhythm Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.